Related Experiment Video
Updated: Feb 19, 2026

Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation
Published on: October 25, 2024
Impact of immune checkpoint inhibition on ovarian reserve
Elizabeth I Buchbinder1, Zihe Song2, Justine V Cohen1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Abstract:
Immune checkpoint inhibition (ICI) has become a mainstay of therapy for various types of malignancy and is being used earlier in the course of therapy. In addition, there are many young women diagnosed with cancers for whom ICI is the standard of care. However, the impact of ICI on fertility is unknown and hard to assess. To evaluate this, we performed an analysis of hormones associated with ovarian reserve in young women with melanoma treated with ipilimumab. Our study showed a reduction in anti-Mullerian hormone, a marker of ovarian reserve, in patients with melanoma treated with either ICI or targeted therapy. These results support the need for further work in this area to better understand the impact these therapies have on fertility.
Insights
Immune checkpoint inhibitors may impact fertility. Young women with melanoma treated with ipilimumab showed reduced anti-Müllerian hormone (AMH), a key ovarian reserve marker, suggesting potential fertility concerns.
Area of Science:
- Oncology
- Reproductive Endocrinology
- Immunotherapy
Background:
- Immune checkpoint inhibitors (ICIs) are standard cancer treatments, including for young women.
- The effects of ICIs on fertility are largely unknown.
- Assessing fertility impact is crucial for this demographic.
Purpose of the Study:
- To evaluate the impact of ipilimumab (an ICI) on ovarian reserve markers in young women with melanoma.
- To investigate potential fertility implications of ICI therapy.
Main Methods:
- Analysis of hormones associated with ovarian reserve.
- Study focused on young women with melanoma treated with ipilimumab.
- Measured anti-Müllerian hormone (AMH) levels.
Main Results:
- A reduction in AMH was observed in patients treated with ipilimumab.
- This reduction was also noted in patients receiving targeted therapy.
- AMH is a significant marker of ovarian reserve.
Conclusions:
- ICI therapy, including ipilimumab, may affect ovarian reserve.
- Further research is needed to fully understand the impact of ICIs on fertility.
- These findings highlight the importance of fertility preservation discussions in cancer care.
More Related Videos
Related Concept Videos
Oogenesis
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of...

